Evidence map›Paper›PMID 36544389›Full record

ArticleTurkish journal of pharmaceutical sciences2022

Pharmacist's Knowledge and Behaviors Toward Pharmacovigilance and Adverse Drug Reactions Reporting Process in Türkiye.

Aslınur Albayrak, Bensu Karahalil

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Aslınur AlbayrakGazi University, Faculty of Pharmacy, Department of Clinical Pharmacy, Ankara, Türkiye.ORCID 0000-0001-5862-4746
Bensu KarahalilGazi University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Ankara, Türkiye.ORCID 0000-0003-1625-6337
Gazi University · TRSüleyman Demirel University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Adverse drug reactions (ADRs) increase patient-related morbidity and mortality. Additionally, it is an important public health problem associated with prolonged hospital stay and increasing economic burden. Pharmacovigilance is central to reducing ADRs, so the development and growth of this science is critical to effective and safe clinical practice. The aim of the study was to evaluate the knowledge and behaviors of pharmacists toward pharmacovigilance and spontaneous ADR notifications in Türkiye. Materials and Methods: The online questionnaire method was used with the pharmacists, whose prior consent was obtained to participate in the study. The survey was uploaded onto Google form. The survey link was distributed electronically to the eligible participants Results: Four hundred six pharmacists (45%) agreed to participate in the study, 81.8% of whose correctly defined correctly defined the term pharmacovigilance. 91.6% knew the name of the Turkish Pharmacovigilance Center. Clinical and hospital pharmacists were found to have a more adequate knowledge than community pharmacists ( Conclusion: These results showed that Turkish pharmacists had adequate knowledge about the concept of pharmacovigilance and the spontaneous ADR reporting system. However, they had little experience in reporting. Training programs should continue to increase the knowledge and reporting experience of pharmacists about the reporting process and requirements.

Indexed as

Adverse drug reaction reporting systembehaviorknowledgepharmacistspharmacovigilance

Identifiers

PMID36544389
PMCPMC9780574
OpenAlexW4214860538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.